Reata Pharmaceuticals is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapies. Co. focuses on therapeutics for the treatment of diseases with few or no approved therapies. Co.'s main programs are in rare forms of chronic kidney disease (CKD) and a rare neurological disease. Co.'s primary product candidates include bardoxolone methyl (bardoxolone) in patients with CKD caused by Alport syndrome and omaveloxolone in patients with a neurological disorder called Friedreich's ataxia. Both bardoxolone and omaveloxolone activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation. The RETA stock yearly return is shown above.
The yearly return on the RETA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RETA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|